These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28392315)

  • 21. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
    Shields RK; Potoski BA; Haidar G; Hao B; Doi Y; Chen L; Press EG; Kreiswirth BN; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2016 Dec; 63(12):1615-1618. PubMed ID: 27624958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam.
    Tamma PD; Fan Y; Bergman Y; Sick-Samuels AC; Hsu AJ; Timp W; Simner PJ; Prokesch BC; Greenberg DE
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29588357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis.
    Sternbach N; Leibovici Weissman Y; Avni T; Yahav D
    J Antimicrob Chemother; 2018 Aug; 73(8):2021-2029. PubMed ID: 29659836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying
    Castanheira M; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031200
    [No Abstract]   [Full Text] [Related]  

  • 26. Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates.
    Castanheira M; Mendes RE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4770-7. PubMed ID: 27216075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IMP-6 Carbapenemase-Producing Enterobacteriaceae Bacteremia Successfully Treated with Amikacin-Meropenem in Two Patients.
    Nakakura I; Ogawa Y; Sakakura K; Imanishi K; Hirota K; Shimatani Y; Uehira T; Nakamori S; Sako R; Doi T; Yamazaki K
    Pharmacotherapy; 2017 Oct; 37(10):e96-e102. PubMed ID: 28699652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
    Wenzler E; Deraedt MF; Harrington AT; Danizger LH
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
    Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
    Shields RK; Nguyen MH; Chen L; Press EG; Kreiswirth BN; Clancy CJ
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam.
    Iacovelli A; Spaziante M; Al Moghazi S; Giordano A; Ceccarelli G; Venditti M
    Infection; 2018 Oct; 46(5):721-724. PubMed ID: 29926399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae.
    Lima O; Sousa A; Longueira-Suárez R; Filgueira A; Taboada-Martínez C; Portela-Pino C; Nodar A; Vasallo-Vidal F; Martinez-Lamas L; Pérez-Landeiro A; Rubianes M; Pérez-Rodríguez MT
    Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1173-1182. PubMed ID: 35939239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
    Veeraraghavan B; Bakthavatchalam YD; Soman R; Swaminathan S; Manesh A; Nagvekar V; Nangia V
    Indian J Med Microbiol; 2021 Jul; 39(3):286-288. PubMed ID: 33892973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.